Scott Gottlieb admitted to not being fully briefed on the US FDA's off-label communications issues, but seems interested in policy tilting toward more information disclosure on drug uses.
The nominee for FDA Commissioner indicated in answers to written questions submitted by members of the Senate Health, Education, Labor...







